Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. An explorative literature review of the multifactorial causes of osteoporosis in epilepsy

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Background: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. Methods: In planned secondary analyses of a 3 months, double-blind, randomized, placebo-controlled trial (n = 45), we explored effects of the GLP-1 receptor agonist exenatide 2 mg once-weekly (n = 23), or placebo (n = 22) on bone turnover markers (BTMs) and BMD in chronic, obese, antipsychotic-treated patients with schizophrenia spectrum disorder. Baseline BTMs were compared to sex- and age-adjusted reference values from a Danish population cohort, and T- and Z-scores were calculated for BMD. Results: In women (n = 24), all baseline BTM measurements of procollagen type I N-terminal propeptide (PINP) and C-terminal cross-linking telopeptide of type I collagen (CTX) were within reference values. In men (n = 21), 5% displayed lower PINP and 14% displayed lower CTX. One patient displayed BMD Z-score < -2, and 23% of patients (17% of women and 29% of men) displayed -2.5 < T-scores < -1 indicating osteopenia, but none had osteoporosis. After treatment, PINP decreased at trend level significance (P = 0.05), and body mass index BMD increased for L2-L4 (P = 0.016). No changes in bone markers were significant after correction for mean prolactin levels. Conclusions: Sex- and age-adjusted measures of bone status in chronic, obese, antipsychotic-treated patients appeared comparable to the reference population. Subtle changes in bone markers during 3 months exenatide treatment may suggest beneficial effects of GLP-1 receptor agonists on bone status in antipsychotic-treated patients, and further studies should consider the potential influence of prolactin.

Original languageEnglish
Article number00781
JournalFrontiers in Psychiatry
Volume9
Issue numberJAN
Pages (from-to)781
ISSN1664-0640
DOIs
Publication statusPublished - 28 Jan 2019

    Research areas

  • Bone mineral density, C-terminal cross-linking telopeptide of type I collagen (CTX), Exenatide, Procollagen type I N-terminal propeptide (PINP), Randomized controlled trial

ID: 57291903